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Available online xxxxObjective: Non-alcoholic fatty liver disease (NAFLD) is the hepatic manifestation of metabolic syndrome. Steroid
hormones and bile acids are potent regulators of hepatic carbohydrate and lipid metabolism. Steroid 5β-
reductase (AKR1D1) is highly expressed in human liver where it inactivates steroid hormones and catalyzes a
fundamental step in bile acid synthesis.
Methods:Human liver biopsies were obtained from34 obese patients and AKR1D1mRNA expression levelswere
measured using qPCR. Genetic manipulation of AKR1D1 was performed in human HepG2 and Huh7 liver cell
lines.Metabolic assessmentsweremade using transcriptome analysis, western blotting,mass spectrometry, clin-
ical biochemistry, and enzyme immunoassays.
Results: In human liver biopsies, AKR1D1 expression decreased with advancing steatosis, ﬁbrosis and inﬂamma-
tion. Expressionwas decreased in patientswith type 2 diabetes. In human liver cell lines,AKR1D1 knockdownde-
creased primary bile acid biosynthesis and steroid hormone clearance. RNA-sequencing identiﬁed disruption of
key metabolic pathways, including insulin action and fatty acid metabolism. AKR1D1 knockdown increased he-
patocyte triglyceride accumulation, insulin sensitivity, and glycogen synthesis, through increased de novo lipo-
genesis and decreased β-oxidation, fueling hepatocyte inﬂammation. Pharmacological manipulation of bile
acid receptor activation prevented the induction of lipogenic and carbohydrate genes, suggesting that the ob-
served metabolic phenotype is driven through bile acid rather than steroid hormone availability.
Conclusions: Genetic manipulation of AKR1D1 regulates the metabolic phenotype of human hepatoma cell lines,
driving steatosis and inﬂammation. Taken together, the observation that AKR1D1mRNA is down-regulated with
advancing NAFLD suggests that it may have a crucial role in the pathogenesis and progression of the disease.
© 2019 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY license (http://
creativecommons.org/licenses/by/4.0/).Keywords:
NAFLD
5β-Reductase
Diabetes
Bile acids
Triglyceride
FXR1. Introduction
The global burden of metabolic disease, including obesity, type 2 di-
abetes mellitus (T2DM) and its hepatic manifestation, non-alcoholic
fatty liver disease (NAFLD), continues to escalate. NAFLD is common,Endocrinology and Metabolism,
. Tomlinson).
nc. This is an open access article undwith an unselected population prevalence of 30%, rising to over 80% in
obese T2DM patients. It is a spectrum of disease ranging from simple
steatosis through to inﬂammation (non-alcoholic steatohepatitis,
NASH) and eventual scarring, ﬁbrosis and cirrhosis with a signiﬁcant
risk of development of hepatocellular carcinoma (HCC) alongside in-
creased cardiovascular mortality [1]. NAFLD is rapidly becoming the
leading indication for liver transplantation [2]. Despite the magnitude
of the clinical problem, deﬁning the precise molecular pathways that
drive lipid accumulation and have potential as therapeutic targets
have proved complex.er the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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tent regulators of metabolic phenotype and have been implicated in
driving hepatic lipid accumulation. Glucocorticoid excess, androgen de-
ﬁciency in men, and androgen excess in women are all associated with
NAFLD [3–5]. Steroid hormone availability is regulated at pre-receptor
level within the liver by a series of enzymes, and both genetic and phar-
macological manipulation of these enzymes has a profound impact
upon metabolic phenotype, including the development of hepatic
steatosis [6–8]. Steroid 5β-reductase (AKR1D1) has an important pre-
receptor role in the regulation of steroid hormone action, however, its
role in regulating metabolic phenotype has not been explored to date
[9]. AKR1D1 is highly expressed in human liver where it generates all
5β-reduced dihydrosteroid metabolites for C19-, C21- and C27-
steroids, i.e. androgens, glucocorticoids, and bile acids [10]. In addition
to its role in steroid hormone clearance, AKR1D1 has a crucial function
in bile acid synthesis. Bile acids are now established as potent signalling
molecules that regulatemetabolic phenotype acting through previously
orphan nuclear receptors, including the farnesoid-X-receptor (FXR). In
addition, oxysterols, including bile acid intermediary substrates, are
able to also activate the liver-X receptors α and β (LXRα, LXRβ) [11].
The activation of both FXR and LXRs have been implicated in the patho-
genesis of NAFLD. FXR deletion results in hepatic steatosis, insulin resis-
tance and hyperglycaemia, with evidence suggesting decreased
expression in NAFLD [12,13], and FXR agonism has already shown
early promise as a therapeutic strategy in NAFLD [14]. In contrast,
LXRα expression is increased in NAFLD [11] and LXRα activation drives
lipid accumulation whilst suppressing the local inﬂammatory response
[15].
AKR1D1 sits at the interface of two fundamentally important path-
ways, steroid hormone metabolism and bile acid synthesis, both being
potent regulators of hepatic metabolic phenotype. The putative role of
AKR1D1 in this regard is almost entirely unexplored; a single study
found an association between increased systemic 5β-reductase activity
and hepatic steatosis [16], another demonstrated decreased hepatic 5β-
reductase expression in diabetic patients [17], whilst a third study re-
ported elevated levels of 7-alpha-hydroxy-4-cholesten-3-one, the bile
acid precursor substrate for AKR1D1, in patients with NAFLD [18].
We have therefore hypothesised that decreases in AKR1D1 activity
and expression will have a detrimental impact upon hepatic metabolic
phenotype, either through decreased bile acid availability or impaired
steroid hormone clearance. We have tested this hypothesis through ge-
netic manipulation of AKR1D1 gene expression as well as investigating
expression in human liver biopsies with established NAFLD.
2. Material and methods
2.1. Human studies
Obesemale (n=7) and female (n=27) individuals undergoingpri-
mary bariatric surgery (laparoscopic sleeve gastrectomy or Roux-en-Y
gastric bypass) were eligible to be recruited into our dedicated bariatric
surgery biobank study (Ref: 16/YH/0247) subject to their written
informed consent. Detailed clinical data (includingweight, height, med-
ical history, medications, family history and alcohol intake) was re-
corded for all participants prior to surgery. Intraoperatively, a wedge
biopsy was taken from the anatomical left lobe of the liver after pneu-
moperitoneumwas established. Half of this tissue was stored in forma-
lin prior to histological analysis by a consultant liver histopathologist
according to Kleiner's NAFLD Activity Score (NAS) and ﬁbrosis staging
classiﬁcation [19]; the remainder was washed in 0.9% NaCl then stored
in RNAlater stabilization solution at−80 °C until RNA extraction.
2.2. Cell culture
HepG2 cells were a gift from Dr. Karl Morten (University of Oxford),
HEK293 cells were a gift from Prof. Anna Gloyn (University of Oxford),Hep3b cells were a gift from Prof Jane McKeating (University of Bir-
mingham) and Huh7 cells were a gift from Dr. Camilla Pramfalk
(Karolinska Institutet). All cells were cultured in Dulbecco's Minimum
Essential Medium (DMEM) (Zen Bio Inc., Durham, NC, USA), containing
4.5 g/L glucose, and supplementedwith 10% fetal bovine serum, 1% pen-
icillin/streptomycin and 1% non-essential amino acids.
The C3A human hepatocyte cell line was purchased from LGC Stan-
dards (ATCC - CRL-10741, Middlesex, UK), and cultured in Eagle's Min-
imum Essential Medium (EMEM) (Sigma-Aldrich, Dorset, UK)
containing 4.5 g/L glucose, and supplemented with 10% fetal bovine
serum, 1% penicillin/streptomycin and 1% non-essential amino acids.
2.3. Primary human hepatocytes
Liver was obtained from patients undergoing surgery who had
consented (NRES Committee South Central; Berkshire B 11/SC/0443)
to the use of excess tissue (resection surplus) for research. Hepatocytes
were dissociated fromwhole liver tissue via a two-stage collagenase di-
gestion as previously described [20]. Cells were diluted to 1million cells
per mL inWilliam's E buffer containing hepatocyte supplements before
plating on Type I collagen coated plates. Cells were collected 24 h post
seeding for RNA isolation.
2.4. Transfection studies
For over-expression transfection studies, 1.6 × 105 cells/well were
plated in 12-well Cell Bind plates (CORNING, Flintshire, UK) for 24 h
prior to transfection with the pCMV6-XL4 + AKR1D1 construct
(Origene Technologies, Rockville, USA). 1 μg DNA construct and 2 μL
X-tremeGENE DNA transfection Reagent (Roche, Hertfordshire, UK)
were diluted in 100 μL OPTIMEM serum-freemedia (Invitrogen, Paisley,
UK). The mixture was vortexed and incubated at room temperature for
20min and, subsequently, 100 μLwas added to eachwell and cells incu-
bated at 37 °C for 48 h prior to treatment.
For knockdown transfection studies, 0.8 × 105 cells/well were plated
in 24-well Cell Bind plates (CORNING, Flintshire, UK) for 24 h prior to
transfection. To prepare siRNA/lipid solutions for each well of a 24-
well plate, 20 nmol of AKR1D1 siRNA (Invitrogen, Paisley, UK) was di-
luted in 25 μL of OPTIMEM serum free media (Invitrogen, Paisley, UK).
In a separate tube, 2.5 μL of Lipofectamine RNAiMAX (Invitrogen, Pais-
ley, UK) was diluted in 25 μL of OPTIMEM. The contents of the two
tubes were combined by gentle pipetting and incubated at room tem-
perature for 5 min. The resulting 50 μL of transfection solution was
added drop-wise. Finally, cells were then incubated at 37 °C for 48 h.
2.5. Cell treatments
Cortisol, cortisone, cholic acid (CA), chenodeoxycholic acid (CDCA),
GW4064, 22(S)-Hydroxycholesterol and GSK2033 were purchased
from Sigma-Aldrich (Dorset, UK). All cell treatments, including bile
acid measurements, were performed in serum-free and phenol-red
free media, containing 4.5 g/L glucose (Zen Bio Inc., Durham, NC, USA).
2.6. Steroid hormone measurements
Cortisone was extracted from cell media after addition of the
internal standard, cortisol-d4. Brieﬂy, transfected cells were incubated
with 200 nMof cortisone for 8 h. 1mL ofmedia was collected, extracted
by SPE and the samples were derivatized overnight to form
methyloxime-trimethylsilylethers (MO-TMS). The ﬁnal derivative was
dissolved in 55 μL cyclohexane, which was transferred to an auto-
sampler vial for gas chromatography–mass spectrometry analysis
using an Agilent 5973 instrument (www.agilent.com) in a selected ion
monitoring mode.
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Total intracellular lipid was extracted and intracellular de novo lipo-
genesis (DNL) measured by the uptake of deuterium from 2H2O
(Finnigan GasBench-II, ThermoFisher Scientiﬁc, UK) into intracellular
triglyceride and PL [2H]-palmitate. [2H]-palmitate enrichments were
determined by gas chromatography–mass spectrometry using a 5890
GC coupled to a 5973 N MSD (Agilent Technologies; CA, USA). Ions
with mass-to-charge ratios (m/z) of 270 (M + 0) and 271 (M + 1)
were determined by selected ion monitoring [21].
2.8. RNA extraction and reverse transcription
Total RNA was extracted from cells using the Tri-Reagent system
(Sigma-Aldrich, Dorset, UK). Concentration was determined spectro-
photometrically at OD260 on a Nanodrop spectrophotometer (Thermo
Scientiﬁc, Hemel Hempstead, UK). Reverse transcriptionwas performed
in a 20 μL volume; 1 μg of total RNA was incubated with 10× RT Buffer,
100 mM dNTP Mix, 10× RT Random Primers, 50 U/μL MultiScribe Re-
verse Transcriptase and 20 U/μL RNase Inhibitor (Thermo Scientiﬁc,
Hemel Hempstead, UK). The reaction was carried out at 25 °C for
10 min, 37 °C for 120 min and then terminated by heating to 85 °C for
5 min.
2.9. Quantitative PCR (qPCR)
All quantitative PCR experiments were conducted using an ABI
7900HT sequence detection system (Perkin-Elmer Applied Biosystems,
Warrington, UK). Reactions were performed in 6 μL volumes on 384-
well plates in reaction buffer containing 3 μL of 2 x Kapa Probe Fast
qPCR Master Mix (Sigma-Aldrich, Dorset, UK). Life Technologies sup-
plied all primers as predesigned TaqMan Gene Expression Assays la-
belled with FAM. The reaction conditions were as follows: 95 °C for
3 min, then 40 cycles of 95 °C for 3 s and 60 °C for 20s. The Ct (dCt) of
each sample using the following calculation (where E is reaction efﬁ-
ciency – determined from a standard curve): ΔCt = E[min Ct-sample Ct]
using the 1/40 dilution from a standard curve generated from a pool
of all cDNAs as the calibrator for all samples. The relative expression
ratio was calculated using the following: Ratio = ΔCt[target]/ΔCt[ref]
and expression values were normalised to 18SrRNA, unless stated oth-
erwise [22].
2.10. RNA sequencing
Total RNA was extracted using the Tri-Reagent system (Sigma-Al-
drich, Dorset, UK) and enriched for polyA-tailed mRNA using oligo
(dT) beads. The Illumina TruSeq Stranded mRNA HT Sample Prep Kit
was used to prepare cDNA libraries for sequencing. In-house 8 bp in-
dexes [23] were used to multiplex samples (10-plex), which were
then sequenced over 1 lane of an Illumina HiSeq4000 machine using
HiSeq 3000/4000 PE Cluster Kit and SBS Kit. Paired-end sequencing
(75 bp) was performed at a depth of ~25 million read pairs per sample.
Reads were mapped with STAR 2.5.1b [24] on default settings with
GENCODE version 19 [25] as transcriptome and GRCh37 as genome ref-
erence. Gene level reads counts for all protein-coding and long
intergenic non-coding RNA (lincRNA) transcripts present in GENCODE
version 19 were quantiﬁed in a strand-speciﬁc manner with
featureCounts [26] from the Subread package v1.5.0-p2. For plotting
purposes, we also normalised the gene counts to transcripts per million
(TPM). Differential expression analysis was performed using limma [27]
in R 3.2.2 on voom-normalised gene counts for all autosomal protein-
coding and lincRNA genes that were expressed at N1 count per million
(CPM) in all knockdown and/or all control samples. A paired model
was ﬁtted to the data, and signiﬁcance was determined by empirical
Bayes moderated t-statistics implemented in limma. Differentiallyregulated genes were deﬁned by a false discovery rate (Benjamini-
Hochberg method) adjusted p-value b1%.
2.11. Protein extraction and Immunoblotting
Total protein was extracted from cells using RIPA buffer (Sigma-Al-
drich, Dorset, UK), protease inhibitor cocktail (1/100) and phosphatase
inhibitor cocktail (1/100) (ThermoFisher Scientiﬁc, Loughborough, UK).
Protein concentrations were measured using a commercially available
assay according to the manufacturer's protocol (Bio-Rad, Hemel Hemp-
stead, UK). Primary β-tubulin (#15115, monoclonal), total AKT (#4685,
monoclonal), pAKT (#4060, monoclonal), AKT1 (#75692, monoclonal),
mTOR (#2983, monoclonal), pGSK3β (#5558, monoclonal), GSK3β
(#12456,monoclonal), ACC (#3662, polyclonal), pACC (#11818, mono-
clonal), IκΒα (#4812, monoclonal) from Cell Signalling (Danvers, USA),
AKR1D1 (dilution 1/250) (HPA057002, polyclonal, Atlas Antibodies AB,
Bromma, Sweden), and secondary antibodies (P044801–2, P044701–2,
polyclonal) from Dako (Agilent Technologies, Santa Clara, USA) were
used at a dilution of 1/1000 and 1/2000 respectively, unless stated oth-
erwise. To ascertain equal gel loading, proteins were normalised to β-
tubulin. Bands were visualised with ECL and ChemiDocXS imager
(Biorad, Hemel Hempstead, UK).Western blots were quantiﬁed by den-
sitometry analysis using Image J (NIH, Bethesda,MD, http://rsb.info.nih.
gov/ij).
2.12. Bile acid measurements
Total bile acid content was measured using a colorimetric assay ac-
cording to the manufacturer's protocol (Cell Biolabs Inc., San Diego,
USA). Total CA and CDCA levels were measured using a competitive
ELISA according to the manufacturer's protocol (Cell Biolabs Inc., San
Diego, USA).
2.13. Biochemical measurements
Glucose, triglyceride and 3-hydroxybutyrate were analyzed using
Instrumentation Laboratory kits on an ILab 650 Clinical Chemistry ana-
lyzer as described previously [28]. Complete medium-containing FBS or
lysis buffer were used as negative background controls. Intracellular
glycogen content was measured using a ﬂuorimetric assay according
to the manufacturer's protocol (BioVision Inc., California, USA).
2.14. Statistics
Data are presented as mean ± standard error. Normal distribution
was conﬁrmed using Shapiro-Wilk test. Statistical analysis on qPCR
data from human subjects was performed using two-tailed, unpaired
t-tests and Fisher's exact t-test. For cell culture experiments, two-
tailed, paired t-tests were used to compare single treatments to control.
For comparisons between control and different treatments, statistical
analysis was performed using one-way analysis of variance (ANOVA)
with Dunnett corrections. To compare mean differences between
groups that had been split on multiple treatments, doses or times,
two-way analysis of variance (ANOVA) with Sidak corrections was
used. Statistical analysis on qPCR data was performed on mean relative
expression ratio values. Data analysis was performed using Graphpad
Prism software (Graphpad Software Inc., La Jolla, USA) and considered
statistically signiﬁcant at p b 0.05.
3. Results
3.1. AKR1D1 mRNA expression decreases across the spectrum of NAFLD in
humans
AKR1D1 mRNA levels were examined in liver biopsies from obese
male and female patients (n=34). A summary of patient characteristics
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vanced ﬁbrosis (F3–4), when compared to mild to moderate ﬁbrosis
(F0–2) (Fig. 1a and b). When biopsies were categorized on the basis of
NAFLD activity score (NAS), reﬂecting the presence of non-alcoholic
steatohepatitis (NASH), as well as on the basis of steatosis percentage,
AKR1D1 mRNA levels were lower in those with higher NAS and N 5.5%
steatosis (the diagnostic threshold for hepatic steatosis [29,30]) (Fig.
1c–d). In addition, when patients were categorized based on the pres-
ence of T2DM, AKR1D1mRNA levelswere signiﬁcantly lower in patients
with T2DM (Fig. 1e). Endorsing our ﬁndings, additional data from pub-
licly available databases were extracted, demonstrating a consistent de-
crease in AKR1D1 expression in patients with advanced NAFLD,
compared to mild NAFLD (Supplementary Fig. 1) (GEO accession
GSE49541; [31,32]).
To deﬁne whether the observed differences in AKR1D1 expression
are sex-speciﬁc, mRNA analysis was repeated in female subjects only.
Consistent with the previous data, in obese female patients, AKR1D1 ex-
pressionwas signiﬁcantly lower in advanced ﬁbrosis (F0–1: 0.85±0.06
vs. F3–4: 0.59 ± 0.09, p = 0.05) and in patients with T2DM (Normal:
0.90 ± 0.07 vs. T2DM: 0.60 ± 0.06, p b 0.01).3.2. AKR1D1 silencing decreases steroid hormone clearance and bile acid
synthesis in human hepatoma cells
In order to investigate the role of AKR1D1 within the human liver
in vitro, the expression pattern of AKR1D1 expression was explored in
four different human hepatoma cell lines, using qPCR (Supplementary
Fig. 2a). Expression levels in HepG2 and Huh7 were similar to those
seen in primary human hepatocytes and these were therefore selected
as suitable models for genetic manipulation studies.
siRNA techniqueswere utilised in both cell lines to decrease AKR1D1
mRNA levels and effective knockdown was conﬁrmed by qPCR and
western blotting (Fig. 2a–c). To conﬁrm the functional impact of
AKR1D1 knockdown on glucocorticoid clearance, HepG2 cells were
treated with cortisone (200 nM, 8 h) and cell culture media cortisone
and 5β-tetrahydrocortisone (5β-reduced metabolite of cortisone, 5β-
THE) levels weremeasured using GC–MS, and compared against scram-
bled controls. Consistent with the mRNA and protein data, AKR1D1
knockdown decreased cortisone clearance and 5β-THE generation
(Supplementary Fig. 2b and c).
Following over-expression of AKR1D1 in HepG2 and HEK293 cells,
cortisone clearance and 5β-THE generation were increased, providing
additional evidence for the potent ability of AKR1D1 to regulate steroid
hormone availability within human hepatoma cells (Supplementary
Figs. 2d–g and 3a–d).Table 1
Clinical and biochemical characteristics of obese patients with mild to moderate ﬁbrosis
(F0–2) compared to patients with advanced ﬁbrosis (F3–4) on liver biopsy.
Characteristics F score p-Value
0–2 3–4
Gender (m/f) f = 21, m = 1 f = 6, m = 6
Age (years) 45 ± 3 49 ± 3 0.32
BMI (kg/m2) 48.8 ± 1.7 48.0 ± 2.3 0.788
T2DM (%) 18 (4/22) 92 (11/12)*** b0.001
AST (IU/L) 22 ± 1 32 ± 5* 0.016
ALT (IU/L) 29 ± 2 37 ± 7 0.167
Platelets (x109/L) 269 ± 11 239 ± 23 0.198
AST/ALT ratio 0.85 ± 0.05 0.92 ± 0.11 0.569
FIB-4 score 0.76 ± 0.08 1.55 ± 0.36** 0.007
Ferritin (ug/L) 102 ± 13 120 ± 20 0.448
HbA1c (%) 5.5 ± 0.1 6.4 ± 0.4** 0.004
Total Chol (mmol/L) 4.6 ± 0.3 4.0 ± 0.3 0.16
HDL (mmol/L) 1.0 ± 0.05 0.8 ± 0.03** 0.008
LDL (mmol/L) 2.8 ± 0.2 2.3 ± 0.3 0.178
Chol/HDL ratio 4.6 ± 0.2 4.8 ± 0.3 0.597As AKR1D1 plays a crucial role in bile acid synthesis, we examined
cell culture media bile acid levels following AKR1D1 knockdown in
both HepG2 andHuh7 cells, revealing decreased total bile acid secretion
in the cell culture media (Fig. 2d). Speciﬁcally, cell media CA and CDCA
levels were reduced (Fig. 2e). In both cell lines, compensatory increases
in themRNA expression of genes involved in primary bile acid synthesis
and transport, including CYP7A1, HSD3B7, CYP8B1 and SLC51A, were ob-
served, in addition to decreases in the expression of the FXR regulated
genes NR0B2 (SHP) and LRH-1, indicating decreased FXR activation
(Fig. 2f and g). Interestingly, a signiﬁcant increase in the mRNA expres-
sion of 5α-reductase type 1 (SRD5A1) was also observed (Fig. 2f and g),
suggesting a compensatory mechanism for either steroid clearance or
bile acid production.
3.3. AKR1D1 silencing deﬁnes discrete dysregulated metabolic pathways
To gain a broader insight into the role of AKR1D1 in human hepa-
toma cells, transcriptome analysis using RNA-sequencing was under-
taken in HepG2 cells with AKR1D1 knockdown. A total of 465
transcriptswere differentially expressed as a function of AKR1D1 knock-
down (p = 4.06 × 10−3; logFC = −4.29) compared to scrambled
control-transfected HepG2 cells. The top 10% of differentially regulated
genes are presented in the heatmap in Fig. 3b. To facilitate wider explo-
ration of molecular processes affected by AKR1D1 knockdown, a differ-
ential expression gene set obtained with a more relaxed signiﬁcance
threshold (FDR 5%) was used to search for enrichment of biological
pathways annotated in the Kyoto Encyclopaedia of Genes and Genomes
(KEGG). This analysis identiﬁed discrete dysregulated metabolic path-
ways impacting upon a variety of cellular phenotypes, notably, includ-
ing key pathways impacting insulin action and fatty acid storage and
utilization (Fig. 3c).
3.4. AKR1D1 knockdown enhances insulin sensitivity in human hepatoma
cells
Informed by our RNA sequencing data, we undertook a series of ex-
periments to deﬁne the precise impact of AKR1D1 silencing on hepatic
insulin sensitivity in vitro. In both HepG2 and Huh7 cells, AKR1D1
knockdown increased themRNAexpression of genes involved in insulin
signalling, including AKT1 and mTOR, whilst it decreased insulin recep-
tor expression (INSR) (Fig. 4a and b). Consistent with these ﬁndings,
AKR1D1 knockdown increased the protein expression of AKT1 and
mTOR in both human hepatoma cell lines, indicative of alterations in
the activation of the insulin signalling cascade (Fig. 4c and d). Endorsing
the changes in protein expression, insulin-stimulated phosphorylation
of PKB/akt at serine 473 was increased in both HepG2 and Huh7 cells
following AKR1D1 knockdown, compared to scrambled controls, in a
dose-dependent manner (5 nM and 50 nM, 15 min) (Fig. 4e and f).
3.5. AKR1D1 knockdown drives hepatocyte triglyceride accumulation
through enhanced lipogenesis and decreased oxidation
Metabolic assessments were made in HepG2 cells following AKR1D1
knockdown. mRNA expression of the glucose transporters GLUT1 and
GLUT9 increased, whilst glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) and glycogen phosphorylase expression (PYGL) decreased
(Fig. 5a). Consistent with these ﬁndings, cell media glucose concentra-
tions were signiﬁcantly lower (scrambled control: 15.34 ± 1.51 vs.
AKR1D1 knockdown: 12.11± 0.90 nmol/mg, p b 0.05) and intracellular
glycogen storage increased (Fig. 5b). However, no differences in the
protein levels of either total or phosphorylated GSK3β were observed,
suggesting that the differences in glycogen accumulation are likely to
be due to decreased glycogenolysis rather than increased glycogen syn-
thesis (Fig. 5c). In addition, we observed signiﬁcant increases in
lipogenic gene expression [fatty acid synthase (FASN), acetyl co-A car-
boxylase (ACC1), stearoyl-CoA desaturase 1 (SCD1) and sterol
Fig. 1. AKR1D1 expression in obese patients. In male (n = 7) and female (n = 27) obese patients, AKR1D1 mRNA expression decreased with more advanced ﬁbrosis (a-b), steatosis
percentage (c) and higher NAFLD Activity Score (NAS) (d). In addition, mRNA expression of AKR1D1 was reduced in patients with T2DM (e). qPCR data were normalised to 18SrRNA,
TBP and ACTB. Data are presented as mean ± se, performed in triplicate, *p b 0.05, **p b 0.01.
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expression of enzymes regulating lipid export [ATP-binding cassette
subfamily A1 (ABCA1)] and oxidation [peroxisome proliferator-
activated receptor α (PPARα)] (Fig. 5a). The pattern of changes in
gene expressionmirrored that observed in theRNA-sequencing analysis
(Supplementary Fig. 4).
Consistent with the mRNA expression data, there were increased
phosphorylated and total protein levels of ACC in AKR1D1 knockdown
HepG2 cells (Fig. 5d). Total cellular triglyceride (TAG) accumulation
also increased (scrambled control: 56.9 ± 8.8 vs. AKR1D1 knockdown:
74.1 ± 9.0 nmol/mg, p b 0.001), whilst fatty acid oxidation decreased,
as measured by reduced 3-hydroxybutyrate concentrations in the cell
culture media (Fig. 5e and f). TAG accumulation in hepatocytes can
occur via a number of different pathways. De novo lipogenesis (DNL)
is the synthesis of fatty acids, namely palmitate (16:0), from non-lipid
precursors and this was measured by incorporation of deuterated
water into cellular TAG and phospholipids. AKR1D1 knockdown in-
creased DNL both in total cellular TAG and in the phospholipid fraction
(Fig. 5g). Complementary metabolic assessments were performed in
Huh7 cells; the results revealed similar changes with increased
lipogenic gene expression, increased ACC protein levels and increased
TAG accumulation, following AKR1D1 knockdown (Supplementary Fig.
5).
Parallel metabolic assessments were made in HepG2 cells over-
expressing AKR1D1. However, no differences in the expression of
genes involved in carbohydrate and lipid metabolism or intracellular
TAG accumulation were observed (Supplementary Fig. 6).
3.6. Metabolic effects of AKR1D1 knockdown are dependent upon reduced
FXR and increased LXR activation
AKR1D1 knockdown signiﬁcantly increased the expression of
CYP7A1, FASN, ACC1, SREBF1, SCD1, AKT1, GLUT1 and GLUT9 in human
hepatoma cells. Cortisol treatment (500 nM, 24 h) of HepG2 cells failed
to regulate the mRNA expression of these genes, suggesting that the
phenotype we observed in our AKR1D1 knockdown experiments wasunlikely to be due to changes in glucocorticoid availability (Supplemen-
tary Fig. 7). Additional treatments with CA (50 μM, 24 h) and CDCA (50
μM, 24 h) were performed. Whilst CA had no effect on gene expression,
CDCA treatment signiﬁcantly prevented the induction of CYP7A1, FASN,
SCD1, SREBF1, AKT1 and GLUT1 mRNA expression caused by AKR1D1
knockdown (Fig. 6a and b).
We therefore tested the hypothesis that the observed phenotype
could arise from decreased FXR activation (due to decreased bile acid
synthesis and availability) or increased LXR activation secondary to in-
creased accumulation of oxysterols and bile acid precursors. We pro-
posed that FXR agonism and/or LXR antagonism would have the
potential to rescue the phenotype in our cells. The FXR agonist
GW4064 (5 μM, 24 h) and the LXRα antagonist 22(S)-
Hydroxycholesterol (22-S HC) (10 μM, 24 h) decreased CYP7A1,
GLUT1, FASN and SCD1 expression, whilst the LXRα antagonist selec-
tively decreased SREBF1 expression (Supplementary Fig. 7). Treatment
with GW4064 normalised the expression of all target genes to levels
seen in scrambled controls (Fig. 6c–j, Supplementary Fig. 8). In addition,
co-treatment with 22-S HC partially restored the expression levels of
FASN, ACC1, SREBF1 and GLUT9. Additional experiments using the
LXRβ antagonist GSK2033 (100 nM, 24 h) resulted in partial rescue of
the expression levels of FASN, ACC1 and SREBF1, but had no impact on
the induction of expression of the other genes caused by AKR1D1 knock-
down (Fig. 6c–j, Supplementary Fig. 8). Taken together, these data pro-
vide strong evidence that the observed metabolic effects following
genetic manipulation of AKR1D1 are mediated by impaired FXR activa-
tion and, to a lesser extent, increased LXR activation.
3.7. AKR1D1 knockdown fuels cellular inﬂammation
Inﬂammation is a key pathogenic process in the natural history and
progression of NAFLD. In HepG2 cells, AKR1D1 knockdown increased
the mRNA expression of the pro-inﬂammatory cytokine IL-8, as well
as increased IL-8 secretion into the cell culture media. In addition,
AKR1D1 knockdown increased the mRNA expression of inducible nitric
oxide synthase (iNOS), which is induced in response to an inﬂammatory
ab
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Fig. 2.Genetic manipulation of AKR1D1 in human hepatoma cell lines and bile acid signalling and synthesis in human hepatoma cell lines, following AKR1D1 knockdown. AKR1D1 knockdown (white bars), decreasedmRNA and protein expression in
both HepG2 and Huh7 cells, as measured by qPCR and western blotting (a-c). In both HepG2 and Huh7 cells, AKR1D1 knockdown (white bars) decreased total bile acid concentrations (d). In addition, AKR1D1 knockdown decreased cholic acid (CA)
and chenodeoxycholic acid (CDCA) concentrations in Huh7 cells (e). Consistent with these, AKR1D1 knockdown increased the mRNA expression of genes involved in classic bile acid synthesis pathway (CYP7A1, HSD3B7, CYP8B1), bile acid transport
(SLC51A), and FXR activation (NR0B2, LRH-1) (f-g). RepresentativeWestern blot images are shown, however formal quantiﬁcationwas performed in n=7–9 replicates. qPCR datawere normalised to 18SrRNA. Data are presented asmean± se of n=
5–8 experiments, performed in triplicate, *p b 0.05, **p b 0.01, ***p b 0.001, compared to scrambled controls (black bars).
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Fig. 3. RNA sequencing analysis in HepG2 cells, following AKR1D1 knockdown. Transcriptomic proﬁling of AKR1D1 knockdown in HepG2 cells. Volcano plot illustrating fold-change in expression (log2FC) against statistical signiﬁcance (–log10
adjusted P-values) for all genes. Red dots represent differentially expressed genes as a function of AKR1D1 knockdown (FDR corrected P-values b0.01) (a). Heat map of the expression changes (normalised counts per million) of the top 10% differ-
entially expressed genes (FDR 1%) in AKR1D1 knockdown HepG2 cells (red and black bars represent up- and down-regulation, respectively) (b). Top KEGG pathways illustrated as a function of the number of differentially expressed genes contrib-
uting to each annotated pathway and coloured with a gradient deﬁned by the statistical signiﬁcance of pathway enrichment (c). (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this
article.)
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Fig. 4. Insulin signalling in human hepatoma cell lines, following AKR1D1 knockdown. AKR1D1 knockdown (white bars) altered the mRNA expression of insulin signalling genes, including AKT1, insulin receptor and mTOR, in both HepG2 (a) and
Huh7 (b) cells, asmeasured by qPCR. AKR1D1 knockdown (white bars) increased the protein expression of both AKT1 andmTOR in both cell lines (c and d). Consistentwith these data, AKR1D1 knockdown, enhanced insulin sensitivitywith increased
insulin-stimulated phosphorylation of AKT andmTOR (15min treatment), in both HepG2 (e) and Huh7 (f) cells. qPCR data were normalised to 18SrRNA and protein data were normalised to β-tubulin. RepresentativeWestern blot images are shown
from 3 biological replicates, however formal quantiﬁcation was performed in n = 7–9 replicates. Gene expression data are presented as mean ± se of n = 7 experiments, performed in triplicate, *p b 0.05, **p b 0.01, ***p b 0.001, compared to
scrambled controls (black bars).
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Fig. 5. Lipid and carbohydrate metabolism in human hepatoma cell lines, following AKR1D1 knockdown. AKR1D1 knockdown (white bars) increased GLUT1 and GLUT9 and decreased GAPDH and glycogen phosphorylase (PYGL) mRNA expression in
HepG2 cells, as measured by qPCR (a). Furthermore, intracellular glycogen storage increased (b), whilst, no differences were observed in total or phosphorylated GSK3β levels, following 15 min insulin stimulation (5 nM, 50 nM) (c). In addition,
AKR1D1 knockdown enhanced lipogenic gene expression (FAS, ACC1, SCD1, SREBF1) (a), reduced the expression of ABCA1 and PPARα (a), and increased total and phosphorylated ACC protein levels (d). Consistent with the lipogenic and PPARα
gene expression, AKR1D1 knockdown increased TAG accumulation in HepG2 cells (e) and reduced fatty acid oxidation, as measured by cell media 3-hydroxybutyrate [3OHB] concentrations (f). Moreover, AKR1D1 knockdown increased de novo
palmitate synthesis in both TAG and phospholipid fraction, as measured by incorporation of 2H from 2H2O into TAG and phospholipid palmitate, respectively (g). Representative Western blot images are shown from 3 biological replicates,
however formal quantiﬁcation was performed in n = 7–9 replicates. qPCR data were normalised to 18SrRNA and protein data were normalised to β-tubulin. Data are presented as mean ± se of n = 7–8 experiments, performed in triplicate, *p
b 0.05, **p b 0.01, ***p b 0.001, compared to scrambled controls (black bars).
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Fig. 6. Incremental gene expression following AKR1D1 knockdown followed by subsequent treatment with CA, CDCA, FXR agonst or LXR antagonist treatment to attempt to rescue the cellular phenotype. CA replacement (50 μM, 24 h) in the cell
culture media failed to prevent upregulation of carbohydrate, lipid or insuling signalling gene expression in AKR1D1 knocked down HepG2 cells (a). In contrast, CDCA replacement (50 μM, 24 h) signiﬁcantly impaired upregulation of the
expression of CYP7A1, FASN, SCD1, SREBF1, AKT1 and GLUT1, in AKR1D1 knocked down HepG2 cells (b). Pharmacological manipulation of the bile acid receptor FXR, using the FXR agonist GW4064 (5 μM, 24 h), also normalised the expression of
CYP7A1, FASN, ACC1, SREBF1, SCD1, AKT1, GLUT1 and GLUT9 to levels seen in scrambled controls (ﬁgure c–h). In addition, treatment with the LXR antagonist 22-S Hydroxycholesterol (22-S HC - 10 μM, 24 h) and the LXRβ antagonist GKS2033
(100 nM, 24 h) partially restored the expression levels of FASN, ACC1 and SREBF1, but had no impact on the induction of expression of the other genes caused by AKR1D1 knockdown (c–h). qPCR data were normalised to 18SrRNA. Data are
presented as mean ± se of incremental gene expression of n= 3–6 experiments, performed in triplicate, *p b 0.05, **p b 0.01, ***p b 0.001 and compared to vehicle treated controls. (KD = AKR1D1 knockdown).
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Fig. 7. Inﬂammatory response in human hepatoma cell lines, following AKR1D1 knockdown. AKR1D1 knockdown (white bars) increased themRNA expression of pro-inﬂammatory cytokines IL-1β, IL-6 and IL-8 as did the expression of iNOS in Huh7
and HepG2 cells, as measured by qPCR (a). AKR1D1 knockdown increased the cell media concentrations of IL-8 in HepG2 cells (b), as well as of IL-6 and IL-8 cell media levels in Huh7 cells (c and d). In addition, AKR1D1 knockdown decreased the
protein expression levels of IκBα, the endogenous inhibitor of NF-κB,which co-ordinates the cellular inﬂammatory response (e). Pharmacologicalmanipulation of the bile acid receptor FXR, using the FXR agonist GW4064 (5 μM, 24 h), normalised the
expression of IL-1β in Huh7 cells, only, whilst it had no effect on the expression of IL-6, IL-8 or iNOS in either Huh7 or HepG2 cells (f). qPCR data were normalised to 18SrRNA, protein levels were normalised to β-tubulin and cell media levels were
corrected to total protein. Representative Western blot images are shown from 3 biological replicates, however formal quantiﬁcation was performed in n = 7–9 replicates. Data are presented as mean ± se of n = 5–8 experiments, performed in
triplicate, *p b 0.05, **p b 0.01, ***p b 0.001, compared to scrambled controls (black bars).
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7a and b). Consistentwith theseﬁndings,AKR1D1knockdown increased
the mRNA expression of iNOS and the expression of the pro-
inﬂammatory cytokines IL-1β and IL-6 in Huh7 cells (Fig. 7a), alongside
increases of both IL-6 and IL-8 secretion in the cell culturemedia (Fig. 7c
and d). Furthermore, protein levels of IκBα (nuclear factor of kappa light
polypeptide gene enhancer in B-cells inhibitor-α), the endogenous in-
hibitor of NF-κB that co-ordinates the cellular inﬂammatory response,
were reduced by AKR1D1 knockdown in Huh7 cells (Fig. 7e).
In order to identify the mechanisms that were responsible for the
regulation of the inﬂammatory response caused by AKR1D1 knock-
down, both HepG2 and Huh7 cells were treated with GW4064 (5μΜ,
24 h) or vehicle, and pro-inﬂammatory cytokine mRNA expression
were explored. In Huh7 cells, GW4064 restored the expression levels
of IL-1β only, but had no impact on the induction of expression of IL-6,
IL-8 or iNOS caused by AKR1D1 knockdown. Similarly, GW4064 failed
to restore cytokine mRNA expression in HepG2 cells, suggesting, in
total, that the inﬂammatory response caused by AKR1D1 knockdown
is not entirely FXR mediated (Fig. 7f).
4. Discussion
Wehave provided the ﬁrst evidence to suggest that AKR1D1 expres-
sion is down-regulated across the spectrum of NAFLD and that this may
be crucial in the pathogenesis of the condition. Our in vitro experiments
have shown that limiting AKR1D1 expression and activity regulates fun-
damental metabolic processes within human hepatoma cells that gov-
ern hepatic insulin sensitivity, lipid accumulation and carbohydrate
metabolism. This leads to a net increase in hepatocyte lipid accumula-
tion and an enhanced inﬂammatory response.
Consistent with our previous study [9], AKR1D1 is able to regulate
glucocorticoid availability in human hepatoma cells, revealing the
presence of an additional pathway for intracellular steroid hormone
metabolism within human liver. In healthy human hepatocytes, gluco-
corticoids can also bemetabolised by a variety of other enzymes, includ-
ing HSD11B1, SRD5A1 and CBR1. However, considering the lack of
expression of HSD11B1 and CBR1 in human hepatoma cells, the poten-
tial contribution of these enzymes in cortisone metabolism, resulting in
differences in the proportion of the 5β-reduced product, may be small,
but cannot be excluded.
Lipid accumulation within hepatocytes is the initial, pre-requisite
step in the development of NAFLD. Fatty acid delivery from adipose tis-
sue lipolysis, arising as a consequence of adipose tissue insulin resis-
tance, remains the predominant source of TAG within hepatocytes,
however, TAG synthesis via DNL increases in importance with NAFLD
severity [34,35]. It is plausible that enhanced glucose uptake with
AKR1D1 knockdown may have fuelled the increase in DNL that we ob-
served. Glucose is the most abundant substrate used for DNL. In addi-
tion, there is clear evidence that limitation of β-oxidation of fatty acids
within hepatocyte mitochondria fuels further TAG accumulation [36].
AKR1D1 knockdown had a dual effect on DNL and β-oxidation. How-
ever, as there is an inverse correlation between hepatic DNL and β-
oxidation, where increased malonyl-CoA production leads to decreased
oxidation via CPT1 inhibition [37], it remains unclear whether the ob-
served decrease in β-oxidation is directly attributable to AKR1D1
knockdown.
In humans, glucose homeostasis is tightly regulated, and abnormal-
ities in hepatic glucose transport have been linked to NAFLD as well as
the development of hepatocellular carcinoma [38,39]. Although GLUT2
is the major glucose transporter in primary human hepatocytes [40],
GLUT1 and GLUT9 are the major contributors to glucose inﬂux in hepa-
toma cells [41]. Gene silencing of AKR1D1 led to increased glucose ﬂux,
with changes in GLUT1 and GLUT9 mRNA expression and reduced cell
media glucose levels, suggesting increased glucose transport into the
cells. Increased glucose transport and changes in glycogen phosphory-
lase are likely to underpin the increase in glycogen we observed.Matching our mechanistic ﬁndings, increased intracellular hepatic gly-
cogen content has been described in obese non-diabetic and T2DM pa-
tients [42,43].
The mechanisms underpinning our observations are complex, and
do not appear to be related to alterations in glucocorticoid availability;
cortisol failed to regulatemost of the genes thatwere regulated as a con-
sequence of AKR1D1 knockdown. In addition, cell treatments with CA
had no effect on gene expression either; however, additional CDCA
treatments prevented the induction of genes involved in lipid and car-
bohydrate metabolism and insulling signalling, following AKR1D1
knockdown. In this regard, the higher potency of CDCA, compared to
CA, to activate FXR is well described [44,45], and our data suggested
that the observed changes are the result of alterations in CDCA produc-
tion and FXR activation. FXR activation represses the activity of genes
involved in TAG synthesis, including inhibition of the expression of
SREBP-1c and FASN [46,47]. Consistent with these ﬁndings, AKR1D1
knockdown increased lipogenic gene expression and these changes
was abolished following GW4064 treatment, suggesting that the effects
of AKR1D1 knockdown on lipidmetabolism are largely, although not ex-
clusively, driven by FXR activation.
The role of FXR in the pathogenesis of metabolic disease and in par-
ticular NAFLD is still not fully understood. Genetic deletion of FXR ex-
pression has shown a detrimental impact on lipid proﬁles, insulin
sensitivity and hepatic steatosis [48,49]. However, these models are
complex, with compensatory increases in bile acid production rates,
which also have the potential to impact the metabolic phenotype
through activation of alternative bile acid receptors, including TGR5, in
a tissue-speciﬁc manner.
At a cellular level, FXR activation supresses SREBP-1c expression in
mice [50], an action that ismediated through small heterodimer partner
(NR0B2/SHP). In our study, although FXR agonism restored SREBF1
mRNA expression in the AKR1D1 knocked down HepG2 cells, no differ-
ences were observed in scrambled control-transfected HepG2 cells,
following GW4064 treatment (Supplementary Fig. 7f). Therefore, po-
tential differences in the regulation of SREBF1 by FXR activation be-
tween rodents and humans cannot be excluded. In parallel, FXR
activation also increases fatty acid oxidation within hepatocytes
through induction of PPARα [51]. FXR has an additional role in regulat-
ing carbohydratemetabolism although some of the published data have
been conﬂicting; FXR agonists can suppress gluconeogenesis and in-
crease glycogen synthesis [52,53], whilst FXR null mice have fasting
hypoglycaemiawith decreased hepatic expression of gluconeogenic en-
zymes as well as decreased hepatic glycogen content [54,55].
If limiting FXR activation by AKR1D1 knockdownwas the onlymech-
anism responsible for our observations, some of our data would conﬂict
with the published literature. Obeticholic acid (semi-synthetic bile acid
analogue) treatment of human liver slices increased the expression of
both SLC51A and B [56], and this mirrors the observations we made in
our AKR1D1 knockdown experiments. An explanation for these ﬁndings
may lie in analysis of the composition of the bile acid pool following
AKR1D1 knockdown. The differing afﬁnities of both primary and sec-
ondary bile acids to activate (or antagonize) bile acid receptors are
well described [57] and, therefore, this may also offer an explanation
as to why our observations are not rescued by simple FXR receptor
agonism. Importantly, in patients with NAFLD, whilst total faecal pri-
mary bile acid levels are increased in comparison with healthy controls,
there is a disproportionate increase in CDCA compared to CA [18] al-
though in this study, circulating bile acid levels were not measured.
The role of LXR receptor activation to regulate lipogenic gene
expression, including SREBF1, FASN, ACC1 and SCD1, has been well de-
scribed [58–60]. In our study, treatment with the LXRα antagonist 22-
S hydroxycholesterol reduced the effect of AKR1D1 knockdown on
lipogenic gene expression, although to a lesser extent when compared
to FXR agonism. The role of LXRβ in hepatic lipogenesis has been con-
ﬂicting. A study from Repa et al. [61] revealed reduced lipogenic gene
expression in LXRα, but not LXRβ, deﬁcient mice; in contrast, in a
79N. Nikolaou et al. / Metabolism Clinical and Experimental 99 (2019) 67–80more recent study, LXβ deﬁciency reduced the effects of the synthetic
LXR ligand T0901317 on lipogenic gene expression in mice [62]. In our
work, LXRβ antagonism partially restored the effects of AKR1D1 knock-
down on lipogenic gene expression, highlighting, in total, the additive
role of LXRs in the metabolic phenotype observed following AKR1D1
knockdown.
Inﬂammation and liver injury are hallmarks in NAFLD/NASH; lipid
accumulation within hepatocytes has also been proposed to trigger
the activation of inﬂammatory pathways [63]. Further insight in
NAFLD pathophysiology has implicated bile acids in the prevalence of
inﬂammation with increased generation of toxic hydrophobic bile
acids that result in cholestatic, inﬂamed livers. In this work, genetic ma-
nipulation of AKR1D1 expression and activity regulated the inﬂamma-
tory response in human hepatoma cells by enhancing the expression
and secretion of pro-inﬂammatory cytokines alongside activation of
the NF-κB pathway. In line with this, a signiﬁcant number of studies
have linked cholestasis and consequent liver inﬂammation and dys-
function with mutations in AKR1D1 [64–66]. It is thought that these
mutations lead to increased levels of bile acid precursors, allo-bile
acids (bile acids produced via 5αR activity) and low levels of CDCA
(due to 27-hydroxylase activity and induction of the alternative path-
way), which can then drive liver injury.
There is increasing evidence on the role of FXR as a regulator of cel-
lular inﬂammation and immune response; activation of the receptor in-
duces the expression of anti-inﬂammatory genes [67] as well as
suppressing NF-κB activation by negative regulation of inﬂammatory
gene expression in the liver [68]. GW4064 has been reported to de-
crease hepatic inﬂammation, both in vitro and in vivo, by reducing the
expression of pro-inﬂammatory cytokines [69,70]. In our study,
GW4064 restored IL-1βmRNA expression in Huh7 cells, only. This ﬁnd-
ing, in combination with the observed IκBa degradation caused by
AKR1D1 knockdown, suggests that AKR1D1 regulates inﬂammatory re-
sponse in a both NF-κB-dependent and NF-κB-independent way of ac-
tion. (Supplementary Fig. 9).5. Conclusions
In conclusion, we have shown that AKR1D1 is down-regulated across
the spectrumof NALFD, and that this drives a detrimental impact on he-
patocyte lipid accumulation and inﬂammation. Further studies are
clearly warranted to explore both themechanisms bywhich this occurs
as well as the potential to manipulate activity to alter NAFLD
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